SCHEMBL5569787

SCHEMBL5569787

[O]C(=O)CCc1ccc(C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
TP53 P04637 1/20 0.52
TSHR P16473 1/20 0.52
RARB P10826 6/20 0.52
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
MAPT P10636 2/20 0.49
RARA P10276 1/20 0.49
MTOR P42345 1/20 0.49
FFAR1 O14842 1/20 0.47
SRD5A2 P31213 1/20 0.46
SELL P14151 1/20 0.45
SELP P16109 1/20 0.45
SELE P16581 1/20 0.45
KEAP1 Q14145 1/20 0.45
PPARA Q07869 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264975 0.84 FFAR1 (0.65) ALDH1A1TP53TSHRRARBFFAR1
Terephthalic Acid SCHEMBL4612225 0.84 TSHR (0.67) ALDH1A1TP53TSHRRARBKMT2A
SCHEMBL70166 0.84 TSHR (0.67) ALDH1A1TP53TSHRRARBKMT2A
Hydrochloric Acid SCHEMBL7132238 0.81 TSHR (0.63) ALDH1A1TP53TSHRRARBKMT2A
SCHEMBL26173527 0.81 ALDH1A1 (0.52) ALDH1A1TP53TSHRRARBKMT2A
SCHEMBL1058497 0.81 ALDH1A1 (0.67) ALDH1A1TP53TSHRRARBKMT2A
SCHEMBL1156726 0.79 KEAP1 (0.70) ALDH1A1KMT2AMAPTFFAR1KEAP1
SCHEMBL133470 0.79 RARB (0.68) ALDH1A1TP53TSHRRARBKMT2A
SCHEMBL371605 0.79 RARB (0.71) ALDH1A1TP53TSHRRARBKMT2A
SCHEMBL1985867 0.78 NPC1 (0.62) ALDH1A1TSHRMAPTFFAR1SRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101027283-A 3,4-disubstituted maleimides for use as vascular damaging agents ASTRAZENECA AB (SE) 2007-08-29 CN disclosed
EP-1742911-A1 3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS AstraZeneca AB (SE) 2007-01-17 EP disclosed
US-7135502-B1 Colchinol derivatives as vascular damaging agents ANGIOGENE PHARMACEUTICALS LTD. (GB) 2006-11-14 US disclosed
US-7125906-B2 Indole derivatives having anti-angiogenetic activity ASTRAZENECA AB (SE) 2006-10-24 US disclosed
US-20060128633-A1 Colchinol derivatives as vascular damaging agents ANGIOGENE PHARMACEUTICALS LTD. 2006-06-15 US disclosed
US-7030123-B2 Indole derivatives with vascular damaging activity ASTRAZENECA AB (SE) 2006-04-18 US disclosed
WO-2005102997-A1 3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS ASTRAZENECA AB (SE) 2005-11-03 WO disclosed
US-6951855-B2 Benzoxazinone derivatives for use in the treatment of angiogenesis ASTRAZENECA AB (SE) 2005-10-04 US disclosed
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization ASTRAZENECA AB (SE) 2005-07-21 US disclosed
EP-1515716-A2 INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY Astrazeneca AB (SE) 2005-03-23 EP disclosed
EP-1385835-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS Astrazeneca AB (SE) 2004-02-04 EP disclosed
US-20030216356-A1 Indole derivatives with vascular damaging activity ASTRAZENECA AB (SE) 2003-11-20 US disclosed
EP-1140745-B1 COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS ANGIOGENE PHARM LTD (GB) 2003-10-22 EP disclosed
WO-2003082271-A2 INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY ASTRAZENECA AB (SE) 2003-10-09 WO disclosed
CN-1431999-A Indole derivatives with vascular damagine activity ASTRAZENECA AB (SE) 2003-07-23 CN disclosed
EP-1289952-A1 INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY AstraZeneca AB (SE) 2003-03-12 EP disclosed
WO-2002085868-A1 BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS ASTRAZENECA AB (SE) 2002-10-31 WO disclosed
WO-2001092224-A1 INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY ASTRAZENECA AB (SE) 2001-12-06 WO disclosed
EP-1140745-A1 COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS Angiogene Pharmaceuticals Ltd (GB) 2001-10-10 EP disclosed
WO-2000040529-A1 COLCHINOL DERIVATIVES AS VASCULAR DAMAGING AGENTS ANGIOGENE PHARMACEUTICALS LTD. (GB) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128633-A1 Colchinol derivatives as vascular damaging agents NR1H3, NR1H2, NR1H4 ALDH1A1 1345/4885TP53 2022/4885TSHR 1786/4885
US-20050159474-A1 Angiogenesis inhibitors for cardiovascular disorders, neovascularization FLT1, FLT4, VEGFA ALDH1A1 1181/4885TP53 3612/4885TSHR 2854/4885
US-20030216356-A1 Indole derivatives with vascular damaging activity IDO1, IDO2, VEGFA ALDH1A1 1818/4885TP53 1738/4885TSHR 1335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.